From prostate to bone: Key players in prostate cancer bone metastasis

Cancers

Volumn 3, Issue 1, 2011, Pages 478-493

  Thobe, Megan N ^a   Clark, Robert J ^a   Bainer, Russell O ^a   Prasad, Sandip M ^a   Rinker Schaeffer, Carrie W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Bone; Chemokines; Metastasis; Prostate

Indexed keywords

BETA 2 MICROGLOBULIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR CXCR7; CXCL16 CHEMOKINE; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF DIFFERENTIATION 1; INTERLEUKIN 6; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SOMATOMEDIN; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

BONE METASTASIS; BONE REMODELING; CANCER CELL; CANCER GROWTH; CANCER MORTALITY; CANCER RESEARCH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPORT; DISEASE MODEL; HUMAN; IN VIVO STUDY; MALE; METASTASIS POTENTIAL; MORBIDITY; NONHUMAN; OSTEOBLAST; PHYSICAL CHEMISTRY; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 79953727024     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3010478     Document Type: Review

References (69)

1. Garcia, M., Jemal, A., Ward, E.M., Center, M.M., Hao, Y., Siegel, R.L., Thun, M.J., Eds. Global Cancer Facts & Figures 2007; American Cancer Society: Atlanta, GA, USA, 2007.
2. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
3. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
4. National Cancer Institute, Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2007), In November 2009 edition; 2010.
5. Bubendorf, L.; Schopfer, A.; Wagner, U.; Sauter, G.; Moch, H.; Willi, N.; Gasser, T.C.; Mihatsch, M.J. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum. Pathol. 2000, 31, 578-583.
6. Coleman, R.E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001, 27, 165-176.
7. Saad, F.; Gleason, D.M.; Murray, R.; Tchekmedyian, S.; Venner, P.; Lacombe, L.; Chin, J.L.; Vinholes, J.J.; Goas, J.A.; Zheng, M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 2004, 96, 879-882.
8. Fizazi, K.; Bosserman, L.; Gao, G.; Skacel, T.; Markus, R. Denosumab treatment of prostate cancer with bone metastases and increased urine n-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase ii trial. J. Urol. 2009, 182, 509-515; discussion 515-506.
9. James, N.D.; Caty, A.; Payne, H.; Borre, M.; Zonnenberg, B.A.; Beuzeboc, P.; McIntosh, S.; Morris, T.; Phung, D.; Dawson, N.A. Final safety and efficacy analysis of the specific endothelin a receptor antagonist zibotentan (zd4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: A double-blind, placebo-controlled, randomized phase ii trial. BJU Int. 2010, 106, 966-973.
10. Nelson, J.B.; Love, W.; Chin, J.L.; Saad, F.; Schulman, C.C.; Sleep, D.J.; Qian, J.; Steinberg, J.; Carducci, M. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008, 113, 2478-2487.
11. Surveillance, epidemiology, and end results (seer) program (http://www.Seer.Cancer.Gov). Seer*stat database: Mortality-all cod, aggregated with state, total U.S. (1969-2007). In National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released June 2010, based on the November 2009 submission. Underlying mortality data provided by NCHS (http://www.cdc.gov/nchs).
12. Bussard, K.M.; Gay, C.V.; Mastro, A.M. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008, 27, 41-55.
13. Klein, C.A. The systemic progression of human cancer: A focus on the individual disseminated cancer cell--the unit of selection. Adv. Cancer Res. 2003, 89, 35-67.
14. Scott, L.J.; Clarke, N.W.; George, N.J.; Shanks, J.H.; Testa, N.G.; Lang, S.H. Interactions of human prostatic epithelial cells with bone marrow endothelium: Binding and invasion. Br. J. Cancer 2001, 84, 1417-1423.
15. Jacobsen, K.; Kravitz, J.; Kincade, P.W.; Osmond, D.G. Adhesion receptors on bone marrow stromal cells: In vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice. Blood 1996, 87, 73-82.
16. Sasaki, A.; Boyce, B.F.; Story, B.; Wright, K.R.; Chapman, M.; Boyce, R.; Mundy, G.R.; Yoneda, T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995, 55, 3551-3557.
17. Fournier, P.G.; Stresing, V.; Ebetino, F.H.; Clezardin, P. How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia 2010, 12, 571-578.
18. Sun, M.; Iqbal, J.; Singh, S.; Sun, L.; Zaidi, M. The crossover of bisphosphonates to cancer therapy. Ann. N. Y. Acad. Sci. 2010, 1211, 107-112.
19. Fournier, P.G.; Chirgwin, J.M.; Guise, T.A. New insights into the role of t cells in the vicious cycle of bone metastases. Curr. Opin. Rheumatol. 2006, 18, 396-404.
20. Mundy, G.R. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2, 584-593.
21. Koeneman, K.S.; Yeung, F.; Chung, L.W. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39, 246-261.
22. Huang, W.C.; Wu, D.; Xie, Z.; Zhau, H.E.; Nomura, T.; Zayzafoon, M.; Pohl, J.; Hsieh, C.L.; Weitzmann, M.N.; Farach-Carson, M.C.; Chung, L.W. Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 2006, 66, 9108-9116.
23. Josson, S.; Matsuoka, Y.; Chung, L.W.; Zhau, H.E.; Wang, R. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin. Cell Dev. Biol. 2010, 21, 26-32.
24. Graham, T.R.; Agrawal, K.C.; Abdel-Mageed, A.B. Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappab, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of mc3t3-e1 osteoblast-like cells. Cancer Sci. 2010, 101, 103-111.
25. Lecrone, V.; Li, W.; Devoll, R.E.; Logothetis, C.; Farach-Carson, M.C. Calcium signals in prostate cancer cells: Specific activation by bone-matrix proteins. Cell Calcium 2000, 27, 35-42.
26. Yuen, H.F.; Chiu, Y.T.; Chan, K.K.; Chan, Y.P.; Chua, C.W.; McCrudden, C.M.; Tang, K.H.; El-Tanani, M.; Wong, Y.C.; Wang, X.; Chan, K.W. Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through id-1. Br. J. Cancer 2010, 102, 332-341.
27. Vandercappellen, J.; Van Damme, J.; Struyf, S. The role of cxc chemokines and their receptors in cancer. Cancer Lett. 2008, 267, 226-244.
28. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; Barrera, J.L.; Mohar, A.; Verastegui, E.; Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56.
29. Nakamura, E.S.; Koizumi, K.; Kobayashi, M.; Saitoh, Y.; Arita, Y.; Nakayama, T.; Sakurai, H.; Yoshie, O.; Saiki, I. Rankl-induced ccl22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor ccr4. Clin. Exp. Metastasis 2006, 23, 9-18.
30. Tokoyoda, K.; Egawa, T.; Sugiyama, T.; Choi, B.I.; Nagasawa, T. Cellular niches controlling b lymphocyte behavior within bone marrow during development. Immunity 2004, 20, 707-718.
31. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. Hiv-1 entry cofactor: Functional cdna cloning of a seven-transmembrane, g protein-coupled receptor. Science 1996, 272, 872-877.
32. Sun, Y.X.; Wang, J.; Shelburne, C.E.; Lopatin, D.E.; Chinnaiyan, A.M.; Rubin, M.A.; Pienta, K.J.; Taichman, R.S. Expression of cxcr4 and cxcl12 (sdf-1) in human prostate cancers (pca) in vivo. J. Cell Biochem. 2003, 89, 462-473.
33. Akashi, T.; Koizumi, K.; Tsuneyama, K.; Saiki, I.; Takano, Y.; Fuse, H. Chemokine receptor cxcr4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci. 2008, 99, 539-542.
34. Chetram, M.A.; Odero-Marah, V.; Hinton, C.V. Loss of pten permits cxcr4-mediated tumorigenesis through erk1/2 in prostate cancer cells. Mol. Cancer Res. 2010, doi:10.1158/1541-7786.MCR-10-0235.
35. Frigo, D.E.; Sherk, A.B.; Wittmann, B.M.; Norris, J.D.; Wang, Q.; Joseph, J.D.; Toner, A.P.; Brown, M.; McDonnell, D.P. Induction of kruppel-like factor 5 expression by androgens results in increased cxcr4-dependent migration of prostate cancer cells in vitro. Mol. Endocrinol. 2009, 23, 1385-1396.
36. Taichman, R.S.; Cooper, C.; Keller, E.T.; Pienta, K.J.; Taichman, N.S.; McCauley, L.K. Use of the stromal cell-derived factor-1/cxcr4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002, 62, 1832-1837.
37. Kukreja, P.; Abdel-Mageed, A.B.; Mondal, D.; Liu, K.; Agrawal, K.C. Up-regulation of cxcr4 expression in pc-3 cells by stromal-derived factor-1alpha (cxcl12) increases endothelial adhesion and transendothelial migration: Role of mek/erk signaling pathway-dependent nf-kappab activation. Cancer Res. 2005, 65, 9891-9898.
38. Engl, T.; Relja, B.; Marian, D.; Blumenberg, C.; Muller, I.; Beecken, W.D.; Jones, J.; Ringel, E.M.; Bereiter-Hahn, J.; Jonas, D.; Blaheta, R.A. Cxcr4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006, 8, 290-301.
39. Sun, Y.X.; Fang, M.; Wang, J.; Cooper, C.R.; Pienta, K.J.; Taichman, R.S. Expression and activation of alpha v beta 3 integrins by sdf-1 /cxc 12 increases the aggressiveness of prostate cancer cells. Prostate 2007, 67, 61-73.
40. Porvasnik, S.; Sakamoto, N.; Kusmartsev, S.; Eruslanov, E.; Kim, W.J.; Cao, W.; Urbanek, C.; Wong, D.; Goodison, S.; Rosser, C.J. Effects of cxcr4 antagonist ctce-9908 on prostate tumor growth. Prostate 2009, 69, 1460-1469.
41. Xing, Y.; Liu, M.; Du, Y.; Qu, F.; Li, Y.; Zhang, Q.; Xiao, Y.; Zhao, J.; Zeng, F.; Xiao, C. Tumor cell-specific blockade of cxcr4/sdf-1 interactions in prostate cancer cells by htert promoter induced cxcr4 knockdown: A possible metastasis preventing and minimizing approach. Cancer Biol. Ther. 2008, 7, 1839-1848.
42. Balabanian, K.; Lagane, B.; Infantino, S.; Chow, K.Y.; Harriague, J.; Moepps, B.; Arenzana-Seisdedos, F.; Thelen, M.; Bachelerie, F. The chemokine sdf-1/cxcl12 binds to and signals through the orphan receptor rdc1 in t lymphocytes. J. Biol. Chem. 2005, 280, 35760-35766.
43. Berahovich, R.D.; Zabel, B.A.; Penfold, M.E.; Lewen, S.; Wang, Y.; Miao, Z.; Gan, L.; Pereda, J.; Dias, J.; Slukvin, II; McGrath, K.E.; Jaen, J.C.; Schall, T.J. Cxcr7 protein is not expressed on human or mouse leukocytes. J. Immunol. 2010, 185, 5130-5139.
44. Borge, M.; Nannini, P.R.; Galletti, J.G.; Morande, P.E.; Avalos, J.S.; Bezares, R.F.; Giordano, M.; Gamberale, R. Cxcl12-induced chemotaxis is impaired in t cells from patients with zap-70-negative chronic lymphocytic leukemia. Haematologica 2010, 95, 768-775.
45. Naumann, U.; Cameroni, E.; Pruenster, M.; Mahabaleshwar, H.; Raz, E.; Zerwes, H.G.; Rot, A.; Thelen, M. Cxcr7 functions as a scavenger for cxcl12 and cxcl11. PLoS One 2010, 5, e9175.
46. Rajagopal, S.; Kim, J.; Ahn, S.; Craig, S.; Lam, C.M.; Gerard, N.P.; Gerard, C.; Lefkowitz, R.J. Beta-arrestin-but not g protein-mediated signaling by the "Decoy" Receptor cxcr7. Proc. Natl. Acad. Sci. USA 2010, 107, 628-632.
47. Burns, J.M.; Summers, B.C.; Wang, Y.; Melikian, A.; Berahovich, R.; Miao, Z.; Penfold, M.E.; Sunshine, M.J.; Littman, D.R.; Kuo, C.J.; Wei, K.; McMaster, B.E.; Wright, K.; Howard, M.C.; Schall, T.J. A novel chemokine receptor for sdf-1 and i-tac involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203, 2201-2213.
48. Wang, J.; Shiozawa, Y.; Wang, Y.; Jung, Y.; Pienta, K.J.; Mehra, R.; Loberg, R.; Taichman, R.S. The role of cxcr7/rdc 1 as a chemokine receptor for cxcl 1 2/sdf-1 in prostate cancer. J. Biol. Chem. 2008, 283, 4283-4294.
49. Grymula, K.; Tarnowski, M.; Wysoczynski, M.; Drukala, J.; Barr, F.G.; Ratajczak, J.; Kucia, M.; Ratajczak, M.Z. Overlapping and distinct role of cxcr7-sdf-1/itac and cxcr4-sdf-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int. J. Cancer 2010, 127, 2554-2568.
50. Kim, C.H.; Kunkel, E.J.; Boisvert, J.; Johnston, B.; Campbell, J.J.; Genovese, M.C.; Greenberg, H.B.; Butcher, E.C. Bonzo/cxcr6 expression defines type 1-polarized t-cell subsets with extralymphoid tissue homing potential. J. Clin. Invest. 2001, 107, 595-601.
51. Tabata, S.; Kadowaki, N.; Kitawaki, T.; Shimaoka, T.; Yonehara, S.; Yoshie, O.; Uchiyama, T. Distribution and kinetics of sr-psox/cxcl16 and cxcr6 expression on human dendritic cell subsets and cd4+ t cells. J. Leukoc. Biol. 2005, 77, 777-786.
52. Nakayama, T.; Hieshima, K.; Izawa, D.; Tatsumi, Y.; Kanamaru, A.; Yoshie, O. Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J. Immunol. 2003, 170, 1136-1140.
53. Hu, W.; Zhen, X.; Xiong, B.; Wang, B.; Zhang, W.; Zhou, W. Cxcr6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of pc3 and lncap cells. Cancer Sci. 2008, 99, 1362-1369.
54. Lu, Y.; Wang, J.; Xu, Y.; Koch, A.E.; Cai, Z.; Chen, X.; Galson, D.L.; Taichman, R.S.; Zhang, J. Cxcl16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol. Cancer Res. 2008, 6, 546-554.
55. Wang, J.; Lu, Y.; Koch, A.E.; Zhang, J.; Taichman, R.S. Cxcr6 induces prostate cancer progression by the akt/mammalian target of rapamycin signaling pathway. Cancer Res. 2008, 68, 10367-10376.
56. Lokeshwar, B.L. Mmp inhibition in prostate cancer. Ann. N. Y. Acad. Sci. 1999, 878, 271-289.
57. Zhang, J.; Dai, J.; Qi, Y.; Lin, D.L.; Smith, P.; Strayhorn, C.; Mizokami, A.; Fu, Z.; Westman, J.; Keller, E.T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 2001, 107, 1235-1244.
58. Asadi, F.; Farraj, M.; Sharifi, R.; Malakouti, S.; Antar, S.; Kukreja, S. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 1996, 27, 1319-1323.
59. Thalmann, G.N.; Sikes, R.A.; Wu, T.T.; Degeorges, A.; Chang, S.M.; Ozen, M.; Pathak, S.; Chung, L.W. Lncap progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 2000, 44, 91-103.
60. Andersen, C.; Bagi, C.M.; Adams, S.W. Intra-tibial injection of human prostate cancer cell line cwr22 elicits osteoblastic response in immunodeficient rats. J. Musculoskelet Neuronal. Interact. 2003, 3, 148-155.
61. Quarmby, V.E.; Beckman, W.C., Jr.; Cooke, D.B.; Lubahn, D.B.; Joseph, D.R.; Wilson, E.M.; French, F.S. Expression and localization of androgen receptor in the r-3327 dunning rat prostatic adenocarcinoma. Cancer Res. 1990, 50, 735-739.
62. Isaacs, J.T.; Isaacs, W.B.; Feitz, W.F.; Scheres, J. Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986, 9, 261-281.
63. Blouin, S.; Basle, M.F.; Chappard, D. Rat models of bone metastases. Clin. Exp. Metastasis 2005, 22, 605-614.
64. Yin, J.; Pollock, C.; Tracy, K.; Chock, M.; Martin, P.; Oberst, M.; Kelly, K. Activation of the ralgef/ral pathway promotes prostate cancer metastasis to bone. Mol. Cell Biol. 2007, 27, 7538-7550.
65. Abate-Shen, C.; Banach-Petrosky, W.A.; Sun, X.; Economides, K.D.; Desai, N.; Gregg, J.P.; Borowsky, A.D.; Cardiff, R.D.; Shen, M.M. Nkx3.1; pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 2003, 63, 3886-3890.
66. Zhou, Z.; Flesken-Nikitin, A.; Corney, D.C.; Wang, W.; Goodrich, D.W.; Roy-Burman, P.; Nikitin, A.Y. Synergy of p53 and rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 2006, 66, 7889-7898.
67. Nemoto, H.; Rittling, S.R.; Yoshitake, H.; Furuya, K.; Amagasa, T.; Tsuji, K.; Nifuji, A.; Denhardt, D.T.; Noda, M. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J. Bone Miner Res. 2001, 16, 652-659.
68. Gingrich, J.R.; Barrios, R.J.; Morton, R.A.; Boyce, B.F.; DeMayo, F.J.; Finegold, M.J.; Angelopoulou, R.; Rosen, J.M.; Greenberg, N.M. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996, 56, 4096-4102.
69. Hsieh, C.L.; Xie, Z.; Yu, J.; Martin, W.D.; Datta, M.W.; Wu, G.J.; Chung, L.W. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. Prostate 2007, 67, 685-691.